SELLAS Life Sciences CEO Pushes Back on Trial Criticism as Shares Fall 7.7%
SLS•SELLAS Life Sciences shares fell 7.7% as CEO criticized trial commentary and emphasized separating noise from clinical data related to the Regal study. The stock also tested key resistance near $16 due to profit-taking after a protracted uptrend and softer overall market risk appetite.
1. CEO Pushback on Regal Trial Criticism
The company’s CEO publicly challenged recent commentary on the Regal clinical trial, urging investors to focus on underlying data quality rather than market noise. This statement was intended to reassure stakeholders after skepticism over interim results led to heightened volatility.
2. Share Performance and Resistance Testing
Shares declined 7.7% following the CEO’s remarks, pressured by profit-taking and broader market weakness. The stock repeatedly encountered resistance around $16, testing that threshold as investors locked in gains after a sustained rally.
